4-溴-2-氯-N-甲基苯甲酰胺 | 893420-23-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-2-氯-N-甲基苯甲酰胺
• 英文名称: 4-bromo-2-chloro-N-methylbenzamide
• 英文别名: 4-bromo-2-chloro-N-methyl-benzamide
• CAS: 893420-23-0
• 化学式: C₈H₇BrClNO
• 分子量: 248.507
• InChiKey: UFLXVXIDMCMCCF-UHFFFAOYSA-N

物化性质

• 沸点：
  318.3±32.0 °C(Predicted)
• 密度：
  1.573±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  4-溴-2-氯-N-甲基苯甲酰胺 在 三氯氧磷 作用下， 以 甲苯 为溶剂， 生成 4-bromo-2-chloro-N-methylbenzimidoyl chloride
  参考文献：
  名称：

  4-Methyl-5-phenyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I

  摘要：

  4-Methyl-5-phenyl-(1,2,4)-triazoles were identified as selective inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1). They were active in vitro and in an in vivo mouse pharmacodynamic (PD) model. The synthesis and structure activity relationships are presented. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.013
• 作为产物：
  描述：

  4-溴-2-氯苯甲酸 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 反应 3.25h， 生成 4-溴-2-氯-N-甲基苯甲酰胺
  参考文献：
  名称：

  NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN, ETC

  摘要：

  本发明提供了作为c-Met蛋白激酶调节剂有用的化合物，以及制备它们的方法，含有它们的药物组合物，以及使用它们进行治疗、预防和/或改善c-Met激酶介导的疾病或疾病的方法。

  公开号：

  US20150057309A1

文献信息

• 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
  申请人：Andrews David

  公开号：US20090099160A1

  公开（公告）日：2009-04-16

  Compounds of the formula (I): wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  化合物的公式（I）：其中变量基团如定义中所述，并描述了药物可接受的盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为产生细胞周期抑制（抗细胞增殖）作用的药物，用于温血动物，如人。
• TRIAZOLE DERIVATIVE OR SALT THEREOF
  申请人：Yoshimura Seiji

  公开号：US20110105460A1

  公开（公告）日：2011-05-05

  [Problem] A compound, which can be used for preventing or treating diseases, in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is concerned, in particular, diabetes, insulin resistance, dementia, schizophrenia and depression, is provided. [Means for Solution] It was found that a triazole derivative, in which one of the 3- and 5-positions of the triazole ring has (di)alkylmethyl or cycloalkyl, each of which is substituted with —O— (aryl or a heterocyclic group, each of which may be substituted, or lower alkylene-cycloalkyl), and the other thereof has aryl, a heterocyclic group or cycloalkyl, each of which may be substituted, or a pharmaceutically acceptable salt thereof exhibits potent 11β-HSD1 inhibitory action. From the above, the triazole derivative of the present invention can be used for preventing or treating diabetes, insulin resistance, dementia, schizophrenia and depression.

  [问题] 提供一种可用于预防或治疗疾病的化合物，其中涉及11β-羟基类固醇脱氢酶1型（11β-HSD1），特别是糖尿病、胰岛素抵抗、痴呆症、精神分裂症和抑郁症。 [解决方案] 发现一种三唑衍生物，其中三唑环的3-和5-位置之一具有（二）烷基甲基或环烷基，每个基团都被取代为-O-（苯基或杂环基，每个基团都可以被取代，或较低的烷基-环烷基），另一个位置具有苯基、杂环基或环烷基，每个基团都可以被取代，或其药学上可接受的盐，表现出强效的11β-HSD1抑制作用。因此，本发明的三唑衍生物可用于预防或治疗糖尿病、胰岛素抵抗、痴呆症、精神分裂症和抑郁症。
• Piperidine derivatives as liver X receptor beta agonists, compositions, and their use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10894775B2

  公开（公告）日：2021-01-19

  In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

  在其许多实施方案中，本发明提供了某些式（I）的哌啶化合物：及其药学上可接受的盐，其中 X、Y、R1、R2、R3、L、R4、L1、Q 和 R5 如本文所定义。本发明的新型化合物以及包含其化合物的药学上可接受的组合物可作为肝 X-β 受体 (LXRβ) 激动剂，并可用于治疗或预防与之相关的病症。这些病症包括但不限于炎症性疾病和以胆固醇和脂质代谢缺陷为特征的疾病，如阿尔茨海默病。
• 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
  申请人：Rhizen Pharmaceuticals SA

  公开号：US11066402B2

  公开（公告）日：2021-07-20

  The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.

  本发明提供了可用作 c-Met 蛋白激酶调节剂的化合物、制备它们的方法、含有它们的药物组合物以及用它们治疗、预防和/或改善 c-Met 激酶介导的疾病或紊乱的方法。
• [EN] NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES<br/>[FR] NOUVEAUX COMPOSÉS 3,5-DISUBSTITUÉS-3H-IMIDAZO[4,5-B]PYRIDINES ET 3,5-DISUBSTITUÉS-3H-[1,2,3]TRIAZOLO[4,5-B]PYRIDINES EN TANT QUE MODULATEURS DES PROTÉINES KINASES C-MET
  申请人：RHIZEN PHARMACEUTICALS SA

  公开号：WO2013144737A3

  公开（公告）日：2013-12-05